In this Bulletin

• Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out
  • New State Bills and Progress Updates
  • Congressional Appropriations Bills Include Language on Psychedelic Therapy, Rollout
  • Colorado Moves Toward Real-World Outcomes Tracking
• RAND Survey: Americans Divided on Psilocybin Legalisation
• New Publications: DMT, Methylone, and Germany’s State-Funded Psilocybin Trial
  • Helus’ Phase 2a Study of Intravenous DMT in MDD Published in Nature Medicine
  • Transcend’s Phase 2 Study of Methylone in PTSD Publishes in JAMA Psychiatry
  • Large German Psilocybin Trial Misses Primary Endpoint
• Latest Data from Aus Reports 188 Patients Treated
• FDA’s ‘One Pivotal Trial’ Default
• Other Stories

***

Policy Round-Up: State Momentum, Congressional Signals, and Colorado’s Data Build-Out

Here, we provide a policy round-up: from state bill updates through to psychedelics’ appearances in Congressional appropriations bills and developments in Colorado’s Natural Medicine Program.

New State Bills and Progress Updates

You can remain current on psychedelics-related bills at the state and federal level in the U.S. by using our new Pα+ Psychedelic Bill Tracker, which, at the time of writing, catalogues around eighty bills. What’s more, for the first few months of the year, we will share a monthly round-up: you can read January’s here.

Here, we are sharing new bills that have been introduced since our last update in Bulletin 219:

• Connecticut SB00191 would make certain modifications to the state’s psychedelic-assisted therapy program.
• West Virginia SB906 is a trigger law bill that would…